The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Open accessAbstract
Background Systemic sclerosis is a rare disabling autoimmune disease with few treatment options. The efficacy and safety of tocilizumab, an interleukin 6 receptor-α inhibitor, was assessed in the faSScinate phase 2 trial in patients with systemic sclerosis.Methods We did this double-blind, placebo-controlled study at 35 hospitals in Canada, France, Germany, the UK, and the USA. We enrolled adults with progressive systemic sclerosis of 5 or fewer years' duration from first non-Raynaud's sign or symptom. Patients were randomly assigned (1:1) to weekly subcutaneous tocilizumab 162 mg or placebo. The primary endpoint was the difference in mean change from baseline in modified Rodnan skin score at 24 weeks. This study is registered with ClinicalTrials.gov, number NCT01532869.Findings We enrolled 87 patients: 43 assigned to tocilizumab and 44 assigned to placebo. The least squares mean change in modified Rodnan skin score at 24 weeks was -3·92 in the tocilizumab group and -1·22 in the placebo group (difference -2·70, 95% CI -5·85 to 0·45; p=0·0915). The least squares mean change at 48 weeks was -6·33 in the tocilizumab group and -2·77 in the placebo group (treatment difference -3·55, 95% CI -7·23 to 0·12; p=0·0579). In one of several exploratory analyses, fewer patients in the tocilizumab group than in the placebo group had a decline in percent predicted forced vital capacity at 48 weeks (p=0·0373). However, we detected no significant difference in disability, fatigue, itching, or patient or clinician global disease severity. 42 (98%) of 43 patients in the tocilizumab group versus 40 (91%) of 44 in the placebo group had adverse events. 14 (33%) versus 15 (34%) had serious adverse events. Serious infections were more common in the tocilizumab group (seven [16%] of 43 patients) than in the placebo group (two [5%] of 44). One patient died in relation to tocilizumab treatment.Interpretation Tocilizumab was not associated with a significant reduction in skin thickening. However, the difference was greater in the tocilizumab group than in the placebo group and we found some evidence of less decline in forced vital capacity. The efficacy and safety of tocilizumab should be investigated in a phase 3 trial before definitive conclusions can be made about its risks and benefits.Funding F Hoffmann-La Roche, Genentech.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The least squares mean change in the score at 24 weeks was −3.92 for the tocilizumab group and −1.22 for the placebo group (difference −2.70, 95% CI: −5.85 to 0.45; p = 0.09), so that the primary endpoint was not attained.”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Khanna et al., 2016
In the citing paper
“In an initial phase 2 double-blind, placebo controlled study tocilizumab did not significant reduce skin thickening (189), but the open label extension phase of this study did show encouraging protective effects on skin thickening and loss of forced vital capacity in SSc patients (190).”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [189]
In the citing paper
“However, fewer patients administered tocilizumab than those administered placebo showed a decline in the percent predicted forced vital capacity at 48 weeks (p = 0.0373).”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Khanna et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationvan Laar, J. M., Farge, D., Sont, J. K., Naraghi, K., Marjanovic, Z., Larghero, J., Schuerwegh, A. J., Marijt, E. W. A., Vonk, M. C., Schattenberg, A. V., et al. (2014) · JAMA · doi:10.1001/jama.2014.6368 · Cited by 766
Self-citationKowal-Bielecka, O., Landewé, R., Avouac, J., Chwiesko, S., Miniati, I., Czirjak, L., Clements, P., Denton, C., Farge, D., Fligelstone, K., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.096677 · Cited by 619
Self-citationMortality and survival in systemic sclerosis: Systematic review and meta-analysis
Rubio-Rivas, M., Royo, C., Simeón, C. P., Corbella, X., & Fonollosa, V. (2014) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2014.05.010 · Cited by 382
Rice, L. M., Padilla, C. M., McLaughlin, S. R., Mathes, A., Ziemek, J., Goummih, S., Nakerakanti, S., York, M., Farina, G., Whitfield, M. L., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77958 · Cited by 351
Self-citationDe Lauretis, A., Sestini, P., Pantelidis, P., Hoyles, R., Hansell, D. M., Goh, N. S. L., Zappala, C. J., Visca, D., Maher, T. M., Denton, C. P., et al. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120725 · Cited by 263
Self-citationPrasse, A., Pechkovsky, D. V., Toews, G. B., Schäfer, M., Eggeling, S., Ludwig, C., Germann, M., Kollert, F., Zissel, G., & Müller‐Quernheim, J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22559 · Cited by 227
Research works printed but not linked: 4
- 1980, Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, Arthritis Rheum, 23, 581
- Steen, 2001, Improvement in skin thickening in systemic sclerosis associated with improved survival, Arthritis Rheum, 44, 2828, 10.1002/1529-0131(200112)44:12<2828::AID-ART470>3.0.CO;2-U · doi:10.1002/1529-0131(200112)44:12<2828::aid-art470>3.0.co;2-u
- Clements, 2000, Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial, Arthritis Rheum, 43, 2445, 10.1002/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q · doi:10.1002/1529-0131(200011)43:11<2445::aid-anr11>3.0.co;2-q
- Steen, 2000, Severe organ involvement in systemic sclerosis with diffuse scleroderma, Arthritis Rheum, 43, 2437, 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U · doi:10.1002/1529-0131(200011)43:11<2437::aid-anr10>3.0.co;2-u
Cited by
Yang (2021) · doi:10.1038/s41598-020-79139-8 · Cited by 5,035
Denton, C. P., & Khanna, D. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30933-9 · Cited by 2,212
Self-citationUpdate of EULAR recommendations for the treatment of systemic sclerosis
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209909 · Cited by 1,104
Self-citationTargeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Translating IL-6 biology into effective treatments
Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 668
Metadata
- Authors
- Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., Allanore, Y., Pope, J. E., Riemekasten, G., Steen, V., Müller-Ladner, U., Lafyatis, R., Stifano, G., Spotswood, H., Chen-Harris, H., Dziadek, S., Morimoto, A., Sornasse, T., Siegel, J., & Furst, D. E.
- Affiliations
- University of Michigan (US)
- University College London (GB)
- Genentech (US)
- University of Utah (US)
- University of Liverpool (GB)
- Jewish General Hospital (CA)
- VA Palo Alto Health Care System (US)
- University of Tübingen (DE)
- UConn Health (US)
- Hôpital Cochin (FR)
- Western University (CA)
- German Rheumatism Research Centre (DE)
- Georgetown University (US)
- Boston University (US)
- Roche (United Kingdom) (GB)
- F. Hoffmann-La Roche AG (CH)
- University of California, Los Angeles (US)
- Corresponding author
- Khanna, Dinesh
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 387
- Issue
- 10038
- Pages
- 2630-2640
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2347093301
- Cited by
- 683
- References
- 40
- Citations by year
- 2026: 29 · 2025: 63 · 2024: 75 · 2023: 54 · 2022: 62 · 2021: 81 · 2020: 99 · 2019: 72 · 2018: 57 · 2017: 69 · 2016: 21
- FWCI
- 65.91
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by-nc-nd)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- systemic sclerosis, tocilizumab, subcutaneous administration, modified Rodnan skin score, skin thickness, forced vital capacity, lung function, adverse events, serious infections, drug safety, treatment efficacy, autoimmune disease, disease-modifying therapy, Raynaud's phenomenon, fatigue, pruritus
- MeSH terms
- Adult, Aged, Canada, Double-Blind Method, Europe, Female, United Kingdom, Humans, Injections, Subcutaneous, Male, Middle Aged, Scleroderma, Systemic, Vital Capacity, Biomarkers, Interleukin-6, Treatment Outcome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(16)00232-4
- The paper
- Khanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., Allanore, Y., Pope, J. E., Riemekasten, G., Steen, V., Müller-Ladner, U., Lafyatis, R., Stifano, G., Spotswood, H., Chen-Harris, H., . . . Furst, D. E. (2016). Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(16)00232-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.